LYRA

Lyra Therapeutics, Inc. (LYRA) Economic Moat Analysis (2026)

Invetso Score: 1.8/10 — Weak · Last Updated: 2026-09-01

Overall Score

Pricing Power

Gross margin remains 100%, but the company still posts deeply negative operating and net margins, indicating no durable pricing power at the operating level.

Revenue per share is only 0.03 while price-to-sales is 0.89, suggesting the business is still not monetizing scale effectively.

Cost Advantage

Operating expenses remain extremely heavy, with SG&A at 28.7% of revenue and R&D at 46.3% of revenue, leaving margins deeply negative.

Asset turnover is only 0.01 and fixed-asset turnover is 0.02, showing very weak operating efficiency.

Switching Costs

No evidence of customer lock-in or recurring revenue durability is visible in the financials.

The company continues to generate negative operating cash flow and negative free cash flow, which does not support a switching-cost moat.

Network Effects

There is no financial evidence of network-driven scale benefits or self-reinforcing user growth.

Low revenue generation and persistent losses suggest the business has not yet reached a network-effect flywheel.

Intangible Assets

Gross margin at 100% may indicate some IP or product differentiation, but it is not translating into sustainable profitability.

R&D intensity is high at 46.3% of revenue, yet returns on capital remain deeply negative, implying the intangible base is not yet a moat.

Efficient Scale

The company is still too small and loss-making to demonstrate efficient-scale advantages.

Negative returns on invested capital and capital employed indicate no evidence of a protected niche with excess returns.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Lyra Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →